Activity of Indatuximab Ravtansine against Triple-Negative Breast Cancer in Preclinical Tumor Models
ConclusionsThese data demonstrate potential use of indatuximab ravtansine in combination with docetaxel or paclitaxel for CD138-positive TNBC.
Source: Pharmaceutical Research - Category: Drugs & Pharmacology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Docetaxel | Drugs & Pharmacology | Myeloma | Taxotere